Menu Close

New clinical trial to test drug for diabetes in reducing risk of alzheimer’s dementia

A new study led through a collaboration between the Diabetes Trials Unit and the Department of Psychiatry at the University of Oxford, and the global healthcare company, Novo Nordisk, will examine whether semaglutide, a tablet used to treat diabetes, can change the course of the earliest change in the brains of people at risk of developing Alzheimer’s dementia